Barr Pharmaceuticals
 | This article needs additional citations for verification. (September 2008) |
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals & Medical Devices |
| Founded | New York (1970) |
| Headquarters | Montvale, NJ, |
Key people | Bruce Downey, CEO |
| Products | Generic and Proprietary Pharmaceuticals |
| Revenue | Over $1 Billion in FY 2005 |
Number of employees | 2000 |
| Parent | Teva Pharmaceutical Industries |
| Website | www |
Barr Pharmaceuticals was a global specialty pharmaceutical company that operated in more than 30 countries worldwide. Barr was engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals, and active pharmaceutical ingredients.
History
Barr Laboratories Inc. was founded in 1970 by Edwin A. Cohen and was ultimately taken public under his leadership.
On July 18, 2008; it was announced that rival firm, Teva Pharmaceutical Industries Ltd. would acquire Barr Pharmaceuticals Inc. for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.[1] Today Barr Laboratories exists only as a sub-division of Teva Pharmaceuticals, as part of the Teva Active Pharmaceutical Ingredients (TAPI) division.
Teva Pharmaceuticals develops and markets generic pharmaceuticals under various brand names, including the Barr Laboratories, Inc. label. Teva Pharmaceuticals is the largest generic drug manufacturer in the world.
References
- ^ Staff (2008-07-21), "Teva Coughs Up $7.46B for Barr Reinforcing Its Number One Spot in the Generics Market", Genetic Engineering & Biotechnology News, GEN News Highlights, Mary Ann Liebert, ISSN 1937-8661, retrieved 2008-09-26